Palatin Technologies, Inc.
PTN, a biopharmaceutical company developing targeted,
receptor-specific peptide therapeutics for the treatment of diseases with
significant unmet medical need and commercial potential, announced today that
the United States Patent and Trademark Office (USPTO) has issued a Notice of
Allowance for U.S. Patent Application Serial Number 13/472,914 (the '914
application). The application includes composition of matter claims on two of
Palatin's most advanced melanocortin receptor-1 specific peptides.
Palatin is conducting in vitro and animal in vivo studies with the peptides
claimed in the allowed patent and with related peptides. Proposed indications
under study include dermatologic indications such as vitiligo and
erythropoietic protoporphyria, inflammatory bowel disease, ocular indications
such as uveitis and dry eye, and nephritis and other kidney conditions.
Palatin plans to designate an initial clinical lead peptide candidate in the
first half of 2013 and start toxicology and other preclinical studies
preparatory to filing an Investigational New Drug Application with the U.S.
Food and Drug Administration.
The peptides claimed in the '914 application are highly specific for the
melanocortin-1 receptor, with sub-nanomolar affinity binding and EC[50]
functional values. The peptides are also highly selective for the
melanocortin-1 receptor, with greater than one thousand times the affinity for
the melanocortin-1 receptor than for the melanocortin-4 or melanocortin-3
receptors.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in